Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Net Income (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Net Income for 3 consecutive years, with -$74.9 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 18.72% to -$74.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$203.8 million through Dec 2025, up 15.64% year-over-year, with the annual reading at -$203.8 million for FY2025, 15.64% up from the prior year.
  • Net Income hit -$74.9 million in Q4 2025 for NewAmsterdam Pharma, down from -$72.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
  • Historically, Net Income has averaged -$51.9 million across 3 years, with a median of -$44.6 million in 2023.
  • Biggest five-year swings in Net Income: surged 64.68% in 2024 and later tumbled 332.54% in 2025.
  • Year by year, Net Income stood at -$49.5 million in 2023, then crashed by 86.34% to -$92.2 million in 2024, then rose by 18.72% to -$74.9 million in 2025.
  • Business Quant data shows Net Income for NAMS at -$74.9 million in Q4 2025, -$72.0 million in Q3 2025, and -$17.4 million in Q2 2025.